Kalkine: EMVision and Dimerix Lead Developments as ASX Health Stocks Ease

Highlights:

• ASX health sector eased, diverging from the broader ASX 200 gains during the week

• EMVision expanded its pivotal trial and welcomed Ramsay Health Care CEO to the board

• Dimerix launched clinical activities in Japan for its rare kidney disease treatment

The ASX Health Care index experienced a modest decline over the past week, moving counter to gains seen in the broader ASX 200, which showed positive movement. This divergence came amid ongoing developments in the global health policy landscape and nearing the end of the Australian financial year, a period often associated with portfolio realignment and tax-related transactions.

EMVision strengthens board and expands global trial footprint

EMVision Medical Devices (ASX:EMV) announced two key developments, reinforcing its strategic direction. Ramsay Health Care (ASX:RHC) CEO Carmel Monaghan has joined EMVision’s board as a non-executive director. With decades of experience across hospital and international operations, Monaghan is expected to add significant value to the organisation’s clinical and commercial network.

EMVision also expanded its pivotal trial for its emu portable brain imaging device, designed for rapid stroke diagnosis. The trial now includes five world-leading hospitals, with the third US site, Mount Sinai Hospital in New York, expected to activate shortly. In Australia, Liverpool Hospital in Sydney is undergoing activation.

The trial aims to support FDA de novo clearance of the emu device. Anticipated milestones over the coming months are focused on trial site activation and ongoing enrolment across all locations.

Dimerix advances kidney disease program in Japan

Dimerix (ASX:DXB) continued its international clinical expansion by initiating a phase III trial site in Japan for its lead candidate DMX-200. The study, titled ACTION3, is targeting treatment for focal segmental glomerulosclerosis (FSGS), a rare and progressive kidney disorder.

The opening of the Japanese site marks a significant development milestone in its partnership with FUSO Pharmaceutical Industries Ltd, the exclusive licensee for the treatment in Japan. FUSO is among several regional licensing collaborators supporting the clinical and commercial pathway of DMX-200.

DMX-200 has already received orphan drug designations in the US, Europe, and through the UK’s ILAP framework. Interim data has previously indicated a favourable efficacy and safety profile, and further enrolment is expected to continue through to the end of next year.

Mayne Pharma deal uncertainty continues

Mayne Pharma (ASX:MYX) faced another turbulent week as its proposed acquisition by US-based Cosette Pharmaceuticals encountered resistance. Mayne received a notice contesting the agreement due to a claim of material adverse change. This back-and-forth triggered fluctuations in share movement over the week.

Despite this, Mayne Pharma has reaffirmed its intention to proceed with a shareholder meeting and vote as planned, pending court decisions on the validity of the claim. The situation remains fluid, with further developments anticipated before the scheduled scheme meeting date.

ReNerve enters product development collaboration

ReNerve (ASX:RNV) revealed a strategic partnership with Berkeley Biologics LLC, a California-based company focused on biologic tissue products. The partnership will bring to market two new tissue-based solutions: one addressing deep dermal human tissue needs, and the other providing amniotic tissue products recognised for regenerative capabilities.

These new offerings will be manufactured in the United States and are expected to align with ReNerve’s existing distribution network, aiming to enhance its value proposition to surgeons treating nerve and tissue trauma. Launch timelines are set for completion before the end of the next calendar year, with expectations for sales growth in subsequent quarters.